Search

AbCellera Biologics Inc

Chiusa

SettoreSettore sanitario

12.38 1.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.04

Massimo

12.49

Metriche Chiave

By Trading Economics

Entrata

-55M

-99M

Vendite

-4.3M

4.1M

EPS

-0.18

Margine di Profitto

-2,434.37

Dipendenti

562

EBITDA

-645K

-42M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+37.36% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

3.7B

Apertura precedente

11.15

Chiusura precedente

12.38

Notizie sul Sentiment di mercato

By Acuity

50%

50%

160 / 340 Classifica in Healthcare

AbCellera Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 ago 2026, 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

25 ago 2026, 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

24 ago 2026, 23:36 UTC

Social Media

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

21 ago 2026, 19:36 UTC

Social Media
Correlated Moves

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

20 ago 2026, 19:16 UTC

Social Media
Correlated Moves

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

19 ago 2026, 23:02 UTC

Social Media

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

18 ago 2026, 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

17 ago 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

14 ago 2026, 19:44 UTC

Social Media
News

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

13 ago 2026, 19:31 UTC

Social Media
News

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

12 ago 2026, 20:02 UTC

Social Media
News

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

11 ago 2026, 22:51 UTC

News

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

10 ago 2026, 23:06 UTC

Correlated Moves
Event
News
Social Media

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

8 ago 2026, 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7 ago 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6 ago 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 ago 2026, 23:02 UTC

Social Media
News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 ago 2026, 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 lug 2026, 19:33 UTC

Correlated Moves
Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 lug 2026, 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 lug 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 lug 2026, 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 lug 2026, 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 lug 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 lug 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 lug 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 lug 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Confronto tra pari

Modifica del prezzo

AbCellera Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

37.36% in crescita

Previsioni per 12 mesi

Media 17.17 USD  37.36%

Alto 30 USD

Basso 9 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbCellera Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

160 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat